Bringing Science to Practice: Therapy Underutilization and Compliance in CV disease - The Aspirin...

Bringing Science to Practice: Therapy Underutilization and Compliance in CV disease - The Aspirin Perspective

Aspirin underuse, poor compliance and cessation

Giuseppe Biondi-Zoccai, MDSapienza University of Rome, Latina, Italy

Melbourne, May 6, 2014 – 16:00 to 19:00 - Room M14, Crown Promenade

Goals of the Roundtable

• Prevalence of non-adherence to Aspirin• Consequences of

non-compliance/discontinuation to Aspirin• Issues surrounding non-compliance to Aspirin• Tools and programs to improve compliance to

Aspirin

Too old to be good?

Too good to be true?

Do we still need Aspirin?

What are the facts?

Goals of the Presentation

• Underutilisation and poor adherence in secondary prevention of CVD

• Physician and patient perceptions about Aspirin

• Impact of Aspirin discontinuation (including inconsistent use and temporary discontinuation)

Updated terminology• Cessation: any ceasing or discontinuance• Compliance: accuracy with which a patient follows an

agreed treatment plan• Discontinuation: physician-supervised withdrawal as

perceived as no longer needed• Disruption: cessation due to non-compliance or bleeding

(brief: 1-5 days; temporary: 6-30 days; permanent: >30 days)

• Interruption: physician-supervised temporary discontinuation for surgery lasting <15 days

• Underuse: act of using (or prescribing) less than expected

Mehran et al, Lancet 2013;382:1714-22

Aspirin use in US secondary prevention

George MG et al, MMWR Morb Mortal Wkly Rep 2012;61 Supp:11-8

Self-reported Aspirin underuse among US patients with established indication

Rivera et al, J Womens Health (Larchmt) 2012;21:379-87

Aspirin compliance in Europe-Latin America

Zaninelli et al, Postgrad Med 2009;121:44-53

Aspirin compliance in Asia-Pacific

Zaninelli et al, Postgrad Med 2010;122:108-17

Focus on post-ACS in China: the BRIG study

Niu et al, Am Heart J 2009;157:709-15.e1

Goals of the Presentation

• Underutilisation and poor adherence in secondary prevention of CVD

• Physician and patient perceptions about Aspirin

• Impact of Aspirin discontinuation (including inconsistent use and temporary discontinuation)

Aspirin for primary prevention in women

Ridker et al, for the Women Health Study Investigators, New Engl J Med 2005;352:1293-304

Aspirin for primary prevention in men

Physicians’ Health Study Investigators, New Engl J Med 1989;321:129-35

Impact on fatal/non-fatal colorectal cancer

Rothwell et al, Lancet 2010;376:1741-50

Benefits vs harms

Patrono et al, Eur Heart J 2013

Some remain skeptical

Cleland et al, Eur Heart J 2013;34:3412-8

Differences between US and Europe

Wolff et al, Ann Intern Med 2009

Differences between US and Europe

Perk et al, Eur Heart J 2012

Underuse in US ambulatory care

Stafford et al, PLoS Med 2005;2:e353

Causes of underuse

Pignone et al, Am J Prev Med 2007;32:403-7

Non-compliance vs discontinuation

Herlitz et al, Am J Cardiovasc Drugs 2010;10:125-41

Perceptions on Aspirin in Europe-Latin America

Zaninelli et al, Postgrad Med 2009;121:44-53

Perceptions on Aspirin in Asia-Pacific

Zaninelli et al, Postgrad Med 2010;122:108-17

Means to improve compliance

Zaninelli et al, Postgrad Med 2009;121:44-53

Goals of the Presentation

• Underutilisation and poor adherence in secondary prevention of CVD

• Physician and patient perceptions about Aspirin

• Impact of Aspirin discontinuation (including inconsistent use and temporary discontinuation)

Ominous impact of aspirin discontinuation

Biondi-Zoccai et al, Eur Heart J 2006;27:2667-74

Discontinuation after stenting

Rossini et al, Am J Cardiol 2011;107:186-94

Impact DAPT discontinuation after stenting

Mehran et al, Lancet 2013;382:1714-22

MYOCARDIAL INFARCTION

CARDIAC DEATH

Discontinuation in UK primary care

Rodriguez et al, BMJ 2011;343:d4094

Discontinuation: thrombotic vs bleeding events

Cea Soriano et al, Thromb Haemost 2013;110:1298-304

Avoiding discontinuation is also cheaper

Cea Soriano et al, Thromb Haemost 2013;110:1298-304

Take home messages• Differentiating between type, reason, setting and

timing of underuse and discontinuation of Aspirin is crucial

• Inadequate physician-patient communication and lack of awareness of underlying cardiovascular risk and benefits are the key reasons for Aspirin underuse and discontinuation

• Underuse and discontinuation are clearly detrimental for patients, especially early after an acute cardiovascular event or procedure, but even later on

Many thanks for your attentionFor any query:

giuseppe.biondizoccai@uniroma1.itgbiondizoccai@gmail.com

For these and other slides:http://www.metcardio.org/slides.html

Reserve slides

ASPREE

• ASPREE is a randomised, double-blind placebo trial of 5-year low-dose (100mg) aspirin for 5 years

• It involves both males and females, 70 years and older • The study is recruiting 19,000 healthy participants through

regional centres (both in urban and rural locations throughout Australia and the United States)

• The trial has a number of sub-studies, which investigate the effect of aspirin on specific diseases: Biobank, ENVIS-ion, ALSOP, SNORE-ASA, ASPREE-AMD, ASPREE-Knee, and ASPREE-NEURO

• Results are expected for 2018

http://www.aspree.org/AUS/aspree-content/aspree-study-details/about-aspree.aspx

Aspirin: a measure of quality of care?

Quality of health care according to the US Institute of Medicine:

degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with professional knowledge

Aspirin discontinuation: a hot topic

Biondi-Zoccai et al, BMJ 2011;343:d3942

Focus on terminology

Mehran et al, Lancet 2013;382:1714-22

Delayed anti-cancer effects

Burn et al, Lancet 2011;378:2081-7

Aspirin as key component of polypills

Wald et al, BMJ 2003;326:1419

Compliance according to indication

VanWormer et al, J Fam Pract 2012;61:525-32

*with 102 (18%) reporting aspirin use

*

Some remain skeptical

Sutcliffe et al, PLoS ONE 2013;8:e81970

Aspirin use in US primary prevention

George MG et al, MMWR Morb Mortal Wkly Rep 2012;61 Supp:11-8

Self-reported Aspirin underuse

Rivera et al, J Womens Health (Larchmt) 2012;21:379-87

Underuse in US ambulatory care

Stafford et al, PLoS Med 2005;2:e353

Self-reported Aspirin underuse

Rivera et al, J Womens Health (Larchmt) 2012;21:379-87

Focus on post-MI in China: the BRIG study

Niu et al, Am Heart J 2009;157:709-15.e1

Aspirin compliance in Europe-Latin America

Zaninelli et al, Postgrad Med 2009;121:44-53

Aspirin compliance in Asia-Pacific

Zaninelli et al, Postgrad Med 2010;122:108-17

Aspirin resistance: fact or fiction?

Biondi-Zoccai et al, BMJ 2008;336:166-7

Aspirin for primary prevention in men

Physicians’ Health Study Investigators, New Engl J Med 1989;321:129-35

Focus on post-ACS in China: the BRIG study

Niu et al, Am Heart J 2009;157:709-15.e1

Resistance or non-compliance?

Schwartz et al, Am J Cardiol 2005;95:973-5

Cumulative incidence after stenting

Mehran et al, Lancet 2013;382:1714-22

Means to improve compliance in Asia-Pacific

• Perceived as effective by most physicians:1. Material demonstrating the lifelong benefits of

Aspirin2. Material demonstrating the immediate effects of

Aspirin3. Shared patient-physician decision-making4. Suitable patient information

Zaninelli et al, Postgrad Med 2010;122:108-17

Discontinuation after stenting

Rossini et al, Am J Cardiol 2011;107:186-94

Discontinuation after stenting

Rossini et al, Am J Cardiol 2011;107:186-94

Discontinuation after stenting

Rossini et al, Am J Cardiol 2011;107:186-94

Discontinuation after stenting

Rossini et al, Am J Cardiol 2011;107:186-94

Avoiding discontinuation is also cheaper

Cea Soriano et al, Thromb Haemost 2013;110:1298-304